Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00723255

Recurrent Endometrial Carcinoma

COMPLETED PHASE2

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01217398

Intraocular Melanoma

UNKNOWN PHASE2

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

NCT02664961

Gestational Trophoblastic Neoplasia Choriocarcinoma Placental Site Trophoblastic Tumor +1 more

TERMINATED PHASE2

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

NCT01114555

Neuroblastoma

COMPLETED PHASE2

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790

Giant Cell Glioblastoma Glioblastoma Gliosarcoma +3 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will receive temozolomide orally once daily for one week, followed by a one-week rest period. This one-week on/one week off schedule will continue for the duration of treatment unless significant side effects develop.

Bevacizumab will be administered intravenously every other week. After eight weeks (two cycles), a CT scan will be performed to see how treatment affected tumor growth.

Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help prevent infection.

Blood tests will be done every other week to evaluate any side effects.

Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan will be performed.

Patients will remain on the study as long as they continue to receive benefit from the treatment and there are no serious side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bevacizumab

Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.

Intervention Type DRUG

Temozolomide

Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically documented locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma
* Measurable disease \> 1cm by spiral computed tomography (CT) or \> 2cm by other radiographic technique
* ECOG performance status of 0-2
* Life expectancy of \> 12 weeks
* Prior treatment with chemotherapy is allowed
* Total bilirubin \< 2.0mg/dl
* AST \< 5x upper limit of normal (ULN)
* Serum creatinine \< 2.0mg/dl
* Absolute neutrophil count \> 1,000/mm3
* Platelets \> 100,000/mm3
* International Normalized Ratio (INR) \< 1.5

Exclusion Criteria

* Prior treatment with temozolomide, decarbazine or bevacizumab
* Clinically apparent central nervous system metastases or carcinomatous meningitis
* Clinically significant cardiovascular disease
* Major surgery, open biopsy, or significant traumatic injury within 28 days
* Pregnant or breast-feeding women
* Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medication
* Serious, nonhealing wound, ulcer or bone fracture
* Evidence of bleeding diathesis or coagulopathy
* History of other disease or metabolic dysfunction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No